Cart
sales@molnova.com
PF-00835231
CAS No. 870153-29-0
PF-00835231( —— )
Catalog No. M28699 CAS No. 870153-29-0
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 128 | In Stock |
|
| 2MG | 70 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 339 | In Stock |
|
| 50MG | 498 | In Stock |
|
| 100MG | 733 | In Stock |
|
| 200MG | 1014 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-00835231
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
DescriptionPF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorglucocerebrosidase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number870153-29-0
-
Formula Weight944.06
-
Molecular FormulaC48H63N8O12
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (529.07 mM)
-
SMILESCC(C)C[C@@H](C(N[C@@H](C[C@H](CCN1)C1=O)C(CO)=O)=O)NC(c1cc(c(OC)ccc2)c2[nH]1)=OCC(C)C[C@@H](C(N[C@@H](C[C@H](CCN1)C1=O)C(CO)=O)=O)NC(c1cc(c(OC)ccc2)c2[nH]1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Neuromedin B
Neuromedin B (NMB) is one of the bombesin (BN)-related peptides in mammals. It was originally purified from pig spinal cords, and it has been shown to be present in central nervous system as well as in gastrointestinal tract.
-
TGFβ1-IN-3
TGFβ1-IN-3, a diarylhydrazone derivative, inhibits fibroblast activation and proliferation, positioning it as a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).
-
R-E-D-V
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion.
